NCT03910946

Brief Summary

identify the prevalence of latent tuberculosis (according to new guideline ;NICE tuberculosis) among these high risk groups of children and notify ministry of health

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2020

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 9, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 10, 2019

Completed
1.2 years until next milestone

Study Start

First participant enrolled

July 1, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2021

Completed
Last Updated

June 16, 2020

Status Verified

June 1, 2020

Enrollment Period

6 months

First QC Date

April 9, 2019

Last Update Submit

June 13, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence of Latent Tuberculosis in High Risk Young Children Attending Pediatric Hospital of Assiut University

    To identify the prevalence of latent tuberculosis (according to new guideline ;NICE tuberculosis) among these high risk groups of children and notify ministry of health

    one year

Study Arms (1)

diabetic and renal

all cases included in the study will be subjected to : Full clinical history to rule out active TB ( history of current prolonged cough, haemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, fatigue.) Chest x ray TST (tuberculin sensitivity test) : injecting a 0.1 mL of liquid containing 5 TU (tuberculin units) PPD (purified protein derivative) into the top layers of skin of the forearm and read skin tests 48-72 hours after the injection

Drug: Tuberculin, Purified Protein 5Unt/0.1 mL Solution

Interventions

Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered

Also known as: mantoux test
diabetic and renal

Eligibility Criteria

Age1 Year - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Patients without active TB sequelae in their CXR

You may qualify if:

  • children aged under 5 yearsold with one of the following risk factor :
  • have diabetes
  • have chronic kidney disease or receive haemodialysis

You may not qualify if:

  • All children aged above 12 years old
  • History of recent contact with TB positive patient
  • All children under 5 yearsold without any other risk factor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015 May 28;372(22):2127-35. doi: 10.1056/NEJMra1405427. No abstract available.

    PMID: 26017823BACKGROUND
  • Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003 May 12;163(9):1009-21. doi: 10.1001/archinte.163.9.1009.

    PMID: 12742798BACKGROUND
  • Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974 Feb;99(2):131-8. doi: 10.1093/oxfordjournals.aje.a121593. No abstract available.

    PMID: 4810628BACKGROUND

MeSH Terms

Conditions

Latent Tuberculosis

Interventions

Tuberculin

Condition Hierarchy (Ancestors)

TuberculosisMycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsLatent Infection

Intervention Hierarchy (Ancestors)

Antigens, BacterialBacterial ProteinsProteinsAmino Acids, Peptides, and ProteinsAntigensBiological Factors

Study Officials

  • nagla h. fargaly, professor

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

nasef s. lemby, physician

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

April 9, 2019

First Posted

April 10, 2019

Study Start

July 1, 2020

Primary Completion

January 1, 2021

Study Completion

February 1, 2021

Last Updated

June 16, 2020

Record last verified: 2020-06